Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…
Discussion
A few weeks ago, I was on a support group call for people with eosinophilic granulomatosis with polyangiitis when someone described how much it meant to be able to talk with other people in the same situation, and my friend responded, “It’s the power of many.” I have not been…
Discussion
Kidney biopsy findings may help identify which adults with severe kidney involvement due to ANCA-associated vasculitis (AAV) are more likely to recover kidney function after treatment, a small study suggests. Data showed that patients with better kidney function at one year had a higher percentage of normal glomeruli —…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
